| Literature DB >> 26903980 |
Víctor S Blancato1, Fernando A Pagliai2, Christian Magni3, Claudio F Gonzalez2, Graciela L Lorca2.
Abstract
The regulator of citrate metabolism, CitO, from Enterococcus faecalis belongs to the FCD family within the GntR superfamily. In the presence of citrate, CitO binds to cis-acting sequences located upstream of the cit promoters inducing the expression of genes involved in citrate utilization. The quantification of the molecular binding affinities, performed by isothermal titration calorimetry (ITC), indicated that CitO has a high affinity for citrate (K D = 1.2 ± 0.2 μM), while it did not recognize other metabolic intermediates. Based on a structural model of CitO where a putative small molecule and a metal binding site were identified, it was hypothesized that the metal ion is required for citrate binding. In agreement with this model, citrate binding to CitO sharply decreased when the protein was incubated with EDTA. This effect was reverted by the addition of Ni(2+), and Zn(2+) to a lesser extent. Structure-based site-directed mutagenesis was conducted and it was found that changes to alanine in residues Arg97 and His191 resulted in decreased binding affinities for citrate, as determined by EMSA and ITC. Further assays using lacZ fusions confirmed that these residues in CitO are involved in sensing citrate in vivo. These results indicate that the molecular modifications induced by a ligand and a metal binding in the C-terminal domain of CitO are required for optimal DNA binding activity, and consequently, transcriptional activation.Entities:
Keywords: Enterococcus; FCD domain; FadR family; citrate; metalloprotein
Year: 2016 PMID: 26903980 PMCID: PMC4746285 DOI: 10.3389/fmicb.2016.00101
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1Graphical representation of the citrate cluster and the domain organization in CitO and its predicted ligand binding pockets. (A) Schematic representation of cit operons. P and P indicate promoter regions, +1 transcriptional start site, black rectangles indicate −10 and −35 boxes, O1 and O2 CitO binding sites. (B) The location of the amino acids selected in CitO for site-directed mutagenesis is indicated. (C) Close view of the residues in CitO predicted to mediate interactions with citrate and Ni2+. CitO in silico modeling (blue) was performed using the structure of TM0439 from Thermotoga maritima (PDB 3FMS, Zheng et al., 2009, cyan) as the template. In a stick representation (orange) are shown the acetate molecules, while as a green sphere is shown the Ni2+ found in TM0439 structure. The model was visualized and analyzed using PyMol.
Bacterial strains, and plasmids used in this study.
| DH5α | F−ϕ80d/ | Invitrogen |
| BL21-Star (DE3) | F− | Novagen |
| JH2-2 (TX4000) | Plasmid-free wild-type strain; Fusr Rifr | Jacob and Hobbs, |
| JHB1 | JH2-2 | Blancato et al., |
| JHB14 | JHB1 carrying pTCV- P | Blancato et al., |
| JHB14-02 | JHB14 carrying pBM02; Emr, Cmr, Kmr | This work |
| JHB14-wt | JHB14 carrying pCitO; Emr, Cmr, Kmr | This work |
| JHB14-64 | JHB14 carrying pCitOQ64A; Emr, Cmr, Kmr | This work |
| JHB14-74 | JHB14 carrying pCitOH74A; Emr, Cmr, Kmr | This work |
| JHB14-97 | JHB14 carrying pCitOR97A; Emr, Cmr, Kmr | This work |
| JHB14-143 | JHB14 carrying pCitOF143A; Emr, Cmr, Kmr | This work |
| JHB14-191 | JHB14 carrying pCitOH191A; Emr, Cmr, Kmr | This work |
| JHB14-214 | JHB14 carrying pCitOL214A; Emr, Cmr, Kmr | This work |
| pET-28a | Expression vector for protein purification; Kmr | Novagen |
| pBM02 | Shuttle vector for gene expression in LAB; Ampr, Cmr | Marelli and Magni, |
| pTCV-lac | Promoterless vector which allows | Poyart and Trieu-Cuot, |
| pET- | pET28a derivative expressing His6-CitO | Blancato et al., |
| pCitO | pBM02 derivative for expressing | Blancato et al., |
| pTCV-P | pTCV-lac carrying | Blancato et al., |
| pET- | pET- | This work |
| pET- | pET- | This work |
| pET- | pET- | This work |
| pET- | pET- | This work |
| pET- | pET- | This work |
| pET- | pET- | This work |
| pCitOQ64A | pCitO with CitO Q64 → A | This work |
| pCitOH74A | pCitO with CitO H74 → A | This work |
| pCitOR97A | pCitO with CitO R97 → A | This work |
| pCitOF143A | pCitO with CitO F143 → A | This work |
| pCitOH191A | pCitO with CitO H191 → A | This work |
| pCitOL214A | pCitO with CitO L214 → A | This work |
Amp.
Oligonucleotides used in this study.
| CitOE-F | GTGTGAGAATATACAAACTTTCGCAG |
| CitOE-R | GGTATACGTTCATTATAGAAAAAACCG |
| CitOQ64A-F | GACGCCCATTCGCTTTGCTTTAGCAGAATTGGTCAAAGAACAATTG |
| CitOQ64A-R | CAATTGTTCTTTGACCAATTCTGCTAAAGCAAAGCGAATGGGCGTC |
| CitOH74A-F | GTCAAAGAACAATTGGTGGAAGCTATACCTATGGTGGGTATCGTG |
| CitOH74A-R | CACGATACCCACCATAGGTATAGCTTCCACCAATTGTTCTTTGAC |
| CitOR97A-F | GCTTATGAAATTTATGATATTGCTAAATCTTTGGACACTTTAGC |
| CitOR97A-R | GCTAAAGTGTCCAAAGATTTAGCAATATCATAAATTTCATAAGC |
| CitOF143A-F | GTAGATGACTTACTACAGAACGCTTCAGATTTTAATTCCTTTATTTATAC |
| CitOF143A-R | GTATAAATAAAGGAATTAAAATCTGAAGCGTTCTGTAGTAAGTCATCTAC |
| CitOH191A-F | CGTAGTATTGCCCTAGAAGAAGCTTGGTTAATTTTCCGCG |
| CitOH191A-R | CGCGGAAAATTAACCAAGCTTCTTCTAGGGCAATACTACG |
| CitOL214A-F | CACTTTTAACCCATGAACATGCAAATCGTTCGCTTCAATTTATTTTG |
| CitOL214A-R | CAAAATAAATTGAAGCGAACGATTTGCATGTTCATGGGTTAAAAGTG |
Figure 2Alanine substitution on the HTH or C-terminal domains of CitO decrease binding to . EMSA were performed using biotin-labeled P (1 ng) and increasing concentrations of CitO-wt or CitO mutants (0.1, 0.2, 0.4 μM), in the presence or absence of citrate (5 mM) as indicated on top of each panel. No protein was added to the first lane.
Figure 3Mutations in the C-terminal of CitO modify its thermal stability in the presence and in the absence of citrate. DSF was performed with purified CitO-wt and its mutant variants (indicated on top of each figure) in the absence or presence of increasing concentrations of citrate (1, 5, 50, 100, or 1000 μM). Purified proteins (20 μM) were subjected to gradually increasing temperatures in the presence of SYPRO Orange fluorophore. Fluorescence intensities were plotted against temperature and transition curves were fitted using the Boltzmann equation.
Figure 4Isothermal titration calorimetric data for the binding of citrate to CitO. Heat changes (upper panel) and integrated peak areas (lower panel) for the injection of a series of aliquots (3 μl) of 1 mM ligand in a solution of 28 μM CitO. Experiments were carried out at 25°C.
Thermodynamic parameters derived from the calorimetric titration of CitO variants with citrate.
| CitO-wt | 1.2 ± 0.2 | 0.44 | 6122 | 47.3 | −7983.4 |
| CitO-Q64A | 0.77 ± 0.1 | 0.27 | 6724 | 50.5 | −8340 |
| CitO-H74A | 0.82 ± 0.04 | 0.33 | 6500 | 50.2 | −8434.6 |
| CitO-R97A | ni | ni | ni | ni | ni |
| CitO-F143A | 0.44 ± 0.08 | 0.34 | 16020 | 82.9 | −8685.7 |
| CitO-H191A | ni | ni | ni | ni | ni |
| CitO-L214A | 1.2 ± 0.2 | 0.123 | 5780 | 46.5 | −8070 |
no interaction.
Figure 5Metal binding to CitO promotes binding to . EMSA were performed using biotin-labeled DNA (1 ng); 0.2 μM CitO-wt (A–D), CitO-R97A, or CitO-H191A (E,F); Me2+ (2 mM) in the absence (A,C,E) or presence of 5 mM citrate (B,D,F). CitO used for (A) and (B), was incubated in buffer and then dialyzed, whereas the CitO-wt or mutants shown in (C–F) were incubated with EDTA for 2 h at 4°C and then dialyzed over night before conducting EMSAs.
Figure 6Amino acid substitutions in CitO affect the modulatory activity of CitO on promoter activity. (A) pBM02 derived plasmids were used to express constitutively CitO and its variants in a citO deficient strain harboring pTCV-PcitCL reporter plasmid. Cells were grown in the presence (gray bars) or absence (black bars) of 17 mM citrate, and assayed for β-galactosidase activity (expressed in arbitrary units, AU) after 6 h of growth. (B) The quantification of the protein levels by Western blot, using polyclonal antibodies against CitO, was performed by densitometry in order to calculate specific β-galactosidase activity. CitO(p) 0.1 μg of purified CitO used as a positive control.